14 Jul 2021 Shedding light on the risks of anticholinergic drugs: NEW information on risk of dementia and harm in the frail elderly
Did you know that 8% of the top 200 drugs prescribed in BC are anticholinergic drugs?
Dr. Aaron M Tejani is a researcher with the Therapeutics Initiative (co-chair of the Education Working Group and the Drug Assessment Working Group), a clinical assistant professor with the Faculty of Pharmaceutical Sciences (University of British Columbia), and Medication use evaluation pharmacist with Lower Mainland Pharmacy Services (Vancouver, BC). He completed his BSc(Pharm) at UBC (Vancouver) and Doctor of Pharmacy degree at Creighton University (Omaha, Nebraska).
This webinar has already taken place. Scroll down to view a video recording of the event.
DATE: Wednesday, July 14, 2021
TIME: 11:45 – 12:45 Pacific Time PDT [UTC -7 convert to your local time]
WHERE: Delivered online using Zoom platform.
CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the evaluation in order to receive your certificate.
Learning Objectives
By the end of this session, participants should be able to:
- Utilize existing tools to determine which drugs have anticholinergic properties.
- Identify subtle and not-so-subtle manifestations on anticholinergic drug toxicity.
- Update on new evidence for the risk of dementia and the risk of harm in the frail elderly
- Describe how indication-based prescribing can help clinicians assess the patients who use anticholinergic drugs.
- Utilize informed consent to ensure patients are aware of the risks associated with use of anticholinergic drugs.
No Comments